We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+0.54%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.46B
AUM Growth
-$483M
Cap. Flow
-$259M
Cap. Flow %
-10.54%
Top 10 Hldgs %
47.28%
Holding
112
New
8
Increased
8
Reduced
35
Closed
24

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$217M
2
IMRX icon
Immuneering
IMRX
+$60.5M
3
TNGX icon
Tango Therapeutics
TNGX
+$37.1M
4
CYTK icon
Cytokinetics
CYTK
+$29.4M
5
TYRA icon
Tyra Biosciences
TYRA
+$20.4M

Top Sells

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$41.1M
2
TWST icon
Twist Bioscience
TWST
+$24.7M
3
XLRN
Acceleron Pharma
XLRN
+$22M
4
MASS icon
908 Devices
MASS
+$21.1M
5
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$13.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.61%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
26
Rocket Pharmaceuticals
RCKT
$387M
$28.9M 1.18%
968,550
– –
CNTA
27
DELISTED
Centessa Pharmaceuticals
CNTA
$28.7M 1.17%
1,727,273
+300,000
+21% +$6.21M
ZYME icon
28
Zymeworks
ZYME
$1.7B
$27.6M 1.12%
950,000
-371,936
-28% -$12.4M
ASND icon
29
Ascendis Pharma A/S
ASND
$16.4B
$27.1M 1.1%
170,000
+95,000
+127% +$13M
ACRS icon
30
Aclaris Therapeutics
ACRS
$851M
$27M 1.1%
1,500,000
-500,000
-25% -$8.02M
AGEN
31
Agenus
AGEN
$312M
$25.2M 1.03%
244,945
– –
IGMS
32
DELISTED
IGM Biosciences
IGMS
$23M 0.94%
350,000
+100,000
+40% +$7.65M
MRTX
33
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$21.2M 0.86%
120,000
-55,000
-31% -$8.85M
AXNX
34
DELISTED
Axonics, Inc. Common Stock
AXNX
$21M 0.85%
322,240
– –
LBPH
35
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$20.2M 0.82%
2,273,221
-48,182
-2% -$444K
CABA icon
36
Cabaletta Bio
CABA
$450M
$19.6M 0.8%
1,611,623
– –
PRAX icon
37
Praxis Precision Medicines
PRAX
$10.3B
$18.9M 0.77%
68,277
+1
+0% +$271
TYRA icon
38
Tyra Biosciences
TYRA
$1.61B
$18.2M 0.74%
+1,069,932
New +$20.4M
VECT
39
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$17.2M 0.7%
2,226,128
– –
TRML
40
DELISTED
Tourmaline Bio
TRML
$16.3M 0.66%
121,585
– –
BPMC
41
DELISTED
Blueprint Medicines
BPMC
$15.4M 0.63%
150,000
-87,546
-37% -$8.15M
ELEV
42
DELISTED
Elevation Oncology
ELEV
$15.1M 0.62%
1,983,165
– –
NBP
43
NovaBridge Biosciences American Depositary Shares
NBP
$197M
$14.5M 0.59%
+200,000
New +$14.5M
YMAB
44
DELISTED
Y-mAbs Therapeutics
YMAB
$14.3M 0.58%
500,000
-300,000
-38% -$9.45M
AKRO
45
DELISTED
Akero Therapeutics
AKRO
$13.4M 0.54%
600,000
– –
GHRS icon
46
GH Research
GHRS
$2.1B
$13.1M 0.53%
608,123
– –
OMER icon
47
Omeros
OMER
$952M
$13.1M 0.53%
950,000
-250,000
-21% -$3.74M
ICVX
48
DELISTED
Icosavax, Inc. Common Stock
ICVX
$12.2M 0.5%
+426,393
New +$14.5M
PHVS icon
49
Pharvaris
PHVS
$2.41B
$12.2M 0.5%
689,731
-55,132
-7% -$944K
CNTB
50
Connect Biopharma Holdings
CNTB
$138M
$11.9M 0.49%
500,000
-150,000
-23% -$3.39M
1
2
3 4 5

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q3 2021 Portfolio in Review

As of Q3 2021, Cormorant Asset Management held 112 positions worth $2.46B, down 16% from $2.94B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Cormorant Asset Management withdrew a net $259M in Q3 2021, closing 24 positions and reducing 35 holdings. Its most notable exit was Twist Bioscience, an estimated $24.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 86% a quarter earlier, followed by Financials.

Against the trend, Cormorant Asset Management opened a new position in Erasca worth $217M.

  • Cormorant Asset Management's largest Q3 2021 buy was Erasca: 10,505,550 shares worth $217M.
  • Cormorant Asset Management added most to Tango Therapeutics in Q3 2021, an estimated $37.1M increase.
  • Cormorant Asset Management's biggest Q3 2021 reduction was Atea Pharmaceuticals, cutting an estimated $41.1M.
  • Cormorant Asset Management fully exited Twist Bioscience in Q3 2021, selling an estimated $24.7M.
  • Cormorant Asset Management's ten largest holdings make up 47% of its $2.46B portfolio in Q3 2021.
  • Cormorant Asset Management opened 8 new positions and closed 24 in Q3 2021.
  • Cormorant Asset Management's portfolio value fell 16% quarter-over-quarter to $2.46B.

Based on Cormorant Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.